» Articles » PMID: 33074770

Monitoring and Maintaining Bone Health in Patients with Turner Syndrome

Overview
Specialty Endocrinology
Date 2020 Oct 19
PMID 33074770
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Subjects affected with Turner Syndrome (TS) suffer low bone mineral density and high risk of fracture from a young age. Estrogen deficiency is considered the main risk factor but other factors, such as intrinsic bone abnormalities, enhanced osteoclastogenesis, vitamin D deficiency and other comorbidities may contribute to the exalted bone fragility.

Areas Covered: The authors performed a literature search in PubMed and EMBASE, using selected key words. They focused their search on pathogenetic mechanisms of osteoporosis in TS and updated the diagnosis, prevention and therapeutic interventions.

Expert Opinion: Bone health is a concern in subjects with TS, and strategies to prevent osteoporosis and fractures should be considered from childhood. Advice on how to live a healthy lifestyle, including physical activity and correct nutrition, should be given during childhood in order to prevent bone impairment later in life. The screening for vitamin D deficiency should be performed between the ages of 9 and 11, and every 2-3 years thereafter. Early initiation of estrogen replacement therapy (ERT) between 11-12 years of age, prompt titration to the adult dose after 2 years, and long-term follow-up to guarantee compliance with ERT, are the key points of osteoporosis prevention in women with TS.

Citing Articles

Lifelong medical challenges and immunogenetics of Turner syndrome.

Cho W Clin Exp Pediatr. 2024; 67(11):560-568.

PMID: 39091155 PMC: 11551602. DOI: 10.3345/cep.2024.00430.


Transition from pediatric to adult care in patients with Turner syndrome in Italy: a consensus statement by the TRAMITI project.

Aversa T, De Sanctis L, Faienza M, Gambineri A, Balducci A, DAprile R J Endocrinol Invest. 2024; 47(7):1585-1598.

PMID: 38376731 PMC: 11196323. DOI: 10.1007/s40618-024-02315-4.


Fracture risk, underlying pathophysiology, and bone quality assessment in patients with Turner syndrome.

Ikegawa K, Hasegawa Y Front Endocrinol (Lausanne). 2022; 13:967857.

PMID: 36325455 PMC: 9618639. DOI: 10.3389/fendo.2022.967857.


Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.

Chiarito M, Piacente L, Chaoul N, Pontrelli P, DAmato G, Grandone A J Endocrinol Invest. 2022; 45(6):1255-1263.

PMID: 35237949 PMC: 9098532. DOI: 10.1007/s40618-022-01760-3.


A patient with Turner syndrome received the percutaneous vertebroplasty seven times: a case report and literature review.

Li L, Shi Y, Zhao N, Liu Z, Zhao Z, Song Z Eur J Med Res. 2021; 26(1):139.

PMID: 34876225 PMC: 8650291. DOI: 10.1186/s40001-021-00617-4.